肥料对饲用高粱的影响

为高粱繁茂的营养生长,需制定适当的肥料施用计划。到目前为止,已完成的研究工作,仅限于有机肥施于饲用高粱,且是在灌溉条件下。但是,在雨养条件下,把有机肥与无机肥一起施用的报道是很少的。因此,为在雨养条件下取得较高产量,找出有机肥与无机肥一起施用的肥源和数量,进行试验。1988和1989年雨季,在印度占西进行,土壤为砂质粘土,pH7.35。土壤有机质(0.46％)含量低,有效氮(175.6公斤/公顷),有效磷(13.4公斤/公顷)和有效钾(202.4公     

提高中蜂蜂蜜纯熟度和蜂群抗病性试验初报

在中蜂标准箱(下称中标箱)基础上略加改进,实现了中蜂贮蜜区与繁殖区分开管理,已较好地克服了夹带子、粉区取蜜而造成的蜂蜜杂质多,浓度低和子脾损伤以及人为传播病原物等问题.     

蜂群的熏烟治螨技术

由于应用二—磷—氯苯基—乙醇杀螨剂治疗由武氏尘螨引起的壁虱病,所以,在蜂群中把烟当作杀螨剂的一种载体已变得非常重要。蜂群的喷烟治疗意即蜂群中的所有蜜蜂都暴露在特定浓度的烟笼罩下的特定空间内。因此,蜂群的熏烟技术必须包括以下几个方面:烟在蜂箱内均匀分布;烟的浓度;蜜蜂对熏烟治疗的抵抗力;尤其应考虑到温     

中华蜜蜂（Apis cerana cerana）泌浆适龄蜂的研究

本文从观察中华蜜蜂（Ａｐｉｓｃｅｒａｎａｃｅｒａｎａ）１～１４日龄各龄工蜂进入王台哺育蜂王幼虫的次数和研究３～１２日龄工蜂王浆腺的重量着手，对中蜂适龄泌浆蜂进行了研究。研究结果显示：中蜂６～８日龄工蜂为适龄泌浆蜂。据此，我们认为：在中蜂生产蜂王浆期间应采取相应的饲养管理措施，培育和维持大量的６～８日龄工蜂，以提高蜂王浆的产量。     

一种安全的取蜂毒装置

引言蜂毒,依每个人的敏感性和被蜂螫的数量,会引起不同程度的过敏反应。这种过敏反应是由一些已查明的成份引起的,因此,把蜂毒或蜂毒的部分成份用于医疗目的是可能的。为此必须开发出适当的方法收取蜂毒,供脱敏和蜂毒生化特性以及可能的医疗用途研究使用。为此,本顿(Benton)等人研制了一种采用电击刺激蜜蜂螫刺行为的装置。用这种装置可采集到大量的蜂毒,但此方法会引起蜜蜂强烈的反应,使得在蜂群附近的人或动物有受蜂螫的危险。为了解决这个问题,研制了下述的取蜂毒装置。     

用塑料台基取代蜂蜡台基育王的研究

从王台接受率、育出王的初生重和卵小管数三个方面对用塑料台基取代蜂蜡台基育王进行了探讨。结果显示：①塑料台基的王台接受率比蜂蜡台基的低，差异极显著（Ｐ＜０．０１）；②塑料台基育出王的初生重卵管数与蜂蜡的差异不显著（Ｐ＞０．０５）；据此，我们认为塑料台基可用于取代蜂蜡台基培育蜂王。     

Proposed criteria for classification of acute myeloid leukemia in dogs and cats

Blood and bone marrow smears from 49 dogs and cats, believed to have myeloproliferative disorders (MPD), were examined by a panel of 10 clinical pathologists to develop proposals for classification of acute myeloid leukemia (AML) in these species. French-American-British (FAB) group and National Cancer Institute (NCI) workshop definitions and criteria developed for classification of AML in humans were adapted. Major modifications entailed revision of definitions of blast cells as applied to the dog and cat, broadening the scope of leukemia classification, and making provisions for differentiating erythremic myelosis and undifferentiated MPD. A consensus cytomorphologic diagnosis was reached in 39 (79.6%) cases comprising 26 of AML, 10 of myelodysplastic syndrome (MDS), and 3 of acute lymphoblastic leukemia (ALL). Diagnostic concordance for these diseases varied from 60 to 81% (mean 73.3 +/- 7.1%) and interobserver agreement ranged from 51.3 to 84.6% (mean 73.1 +/- 9.3%). Various subtypes of AML identified included Ml, M2, M4, M5a, M5b, and M6. Acute undifferentiated leukemia (AUL) was recognized as a specific entity. M3 was not encountered, but this subclass was retained as a diagnostic possibility. The designations M6Er and MDS-Er were introduced where the suffix "Er" indicated preponderance of erythroid component. Chief hematologic abnormalities included circulating blast cells in 98% of the cases, with 36.7% cases having >30% blast cells, and thrombocytopenia and anemia in approximately 86 to 88% of the cases. Bone marrow examination revealed panmyeloid dysplastic changes, particularly variable numbers of megaloblastoid rubriblasts and rubricytes in all AML subtypes and increased numbers of eosinophils in MDS. Cytochemical patterns of neutrophilic markers were evident in most cases of Ml and M2, while monocytic markers were primarily seen in M5a and M5b cases. It is proposed that well-prepared, Romanowsky-stained blood and bone marrow smears should be examined to determine blast cell types and percentages for cytomorphologic diagnosis of AML. Carefully selected areas of stained films presenting adequate cellular details should be used to count a minimum of 200 cells. In cases with borderline diagnosis, at least 500 cells should be counted. The identity of blast cells should be ascertained using appropriate cytochemical markers of neutrophilic, monocytic, and megakaryocytic differentiation. A blast cell count of > 30% in blood and/or bone marrow indicates AML or AUL, while a count of < 30% blasts in bone marrow suggests MDS, chronic myeloid leukemias, or even a leukemoid reaction. Myeloblasts, monoblasts, and megakaryoblasts comprise the blast cell count. The FAB approach with additional criteria should be used to distinguish AUL and various subtypes of AML (Ml to M7 and M6Er) and to differentiate MDS, MDS-ER, chronic myeloid leukemias, and leukemoid reaction. Bone marrow core biopsy and electron microscopy may be required to confirm the specific diagnosis. Immunophenotyping with lineage specific antibodies is in its infancy in veterinary medicine. Development of this technique is encouraged to establish an undisputed identity of blast cells. Validity of the proposed criteria needs to be substantiated in large prospective and retrospective studies. Similarly, clinical relevance of cytomorphologic, cytochemical, and immunophenotypic characterizations of AML in dogs and cats remains to be determined.